Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

According to reports, a cause for concern is that 51 of the cases involve infants under one year of age, while 553 are among ...

There has been a noticeable increase in the spread of Chikungunya in the city of Colombo, Kotte, and the suburbs of Colombo, ...

Chikungunya is a mosquito-borne illness named for the joint pain it causes, according to the Cleveland Clinic. Most people infected by a mosquito bite recover from the illness in about one week ...